Skip to main content
SpringerLink
Log in

Allergen-Specific Immunotherapy (AIT)

  • Chapter
  • First Online:
Textbook of Allergen Tolerance

  • 330 Accesses

Abstract

This chapter focuses on allergen-specific immunotherapy (AIT). AIT is the administration of gradually increasing doses of the causative allergen to treat atopic diseases until a maintenance dosage is achieved and long-term remission and allergen tolerance established. AIT has over 100 years of history after Leonard Noon (1877–1913) invented this method. Nowadays, we see the process of improving allergen quality, constituting new medication combinations and administration protocols, expanding research of allergen tolerance after AIT, accumulating clinical experience, etc.

From this perspective, the principal purpose of the AIT’s development is to shorten existing long protocols with no significant loss of efficacy, create a better adverse effect profile, and spread AIT in developing countries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Durham S, Nelson H. Allergen immunotherapy: a centenary celebration. World Allergy Organ J. 2011;4(6):104–6. https://doi.org/10.1097/WOX.0b013e3182218920.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Pfaar O, Lou H, Zhang Y, Klimek L, Zhang L. Recent developments and highlights in allergen immunotherapy. Allergy. 2018;73:2274–89. https://doi.org/10.1111/all/13652.

    Article  PubMed  Google Scholar 

  3. Gunawardana NC, Durham SR. New approaches to allergen immunotherapy. Ann Allergy Asthma Immunol. 2018;121:293–305. https://doi.org/10.1016/j.anai.2018.07.014.

    Article  CAS  PubMed  Google Scholar 

  4. Akinfenwa O, Rodriguez-Dominguez A, Vrtala S, Valenta R, Campana R. Novel vaccines for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2021;21(1):86–99. https://doi.org/10.1097/ACI.0000000000000706.

    Article  CAS  PubMed  Google Scholar 

  5. Freeman J. Leonard Noon. Int Arch Allergy Appl Immunol. 1953;4:282–4.

    Article  CAS  Google Scholar 

  6. Noon L, Cantab BC. Prophylactic inoculation against hay fever. Lancet. 1911;177(4580):1572–3. https://doi.org/10.1016/s0140-6736(00)78276-6.

    Article  Google Scholar 

  7. Freeman J. Rush inoculation with special reference to hay fever treatment. Lancet. 1930;1:744.

    Article  Google Scholar 

  8. Frankland AW, Augustin R. Prophylaxis of summer hayfever and asthma: controlled trial comparing crude grass pollen extracts with isolated main protein component. Lancet. 1954;1:1055.

    Article  Google Scholar 

  9. Klimek L, Brehler R, Hamelmann E, Kopp M, Ring J, Treudler R, et al. Development of subcutaneous allergen immunotherapy (part 2): preventive aspects and innovations. Allergo J Int. 2019;28:107–19. https://doi.org/10.1007/s40629-019-0097-z.

    Article  Google Scholar 

  10. Vogelberg C, Brueggenjuergen B, Richter H, Jutel M. Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: a retrospective real-life, long-term cohort analysis. Eur Respir J. 2020;56:243. https://doi.org/10.1183/13993003.congress-2020.243.

    Article  Google Scholar 

  11. Castro-Almarales RL, Ronquillo-Díaz M, Álvarez-Castelló M, Rodríguez-Canosa J, González-León M, Enríquez-Domínguez I, et al. Subcutaneous allergen immunotherapy for asthma: a randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine. World Allergy Organ J. 2020;13:100098. https://doi.org/10.1016/j.waojou.2020.100098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ohashi-Doi K, Lund K, Mitobe Y, Okamiya K. State of the art: development of a sublingual allergy immunotherapy tablet for allergic rhinitis in Japan. Biol Pharm Bull. 2020;43(1):41–8.

    Article  CAS  Google Scholar 

  13. Caffarelli C, Mastrorilli C, Procaccianti M, Santoro A. Use of sublingual immunotherapy for aeroallergens in children with asthma. J Clin Med. 2020;9:3381. https://doi.org/10.3390/jcm9103381.

    Article  CAS  PubMed Central  Google Scholar 

  14. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo Y, Yohalakshmi C, Ward D, Segal JB, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309(12):1278–88. https://doi.org/10.1001/jama.2013.2049.

    Article  CAS  PubMed  Google Scholar 

  15. Głobińska A, Boonpiyathad T, Satitsuksanoa P, Kleuskens M, van der Veen W, Sokolowska M, Akdis M. Mechanisms of allergen-specific immunotherapy. Diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 2018;121:306–12. https://doi.org/10.1016/j.anai.2018.06.026.

    Article  CAS  PubMed  Google Scholar 

  16. Mäntylä J, Thomander T, Hakulinen A, Kukkonen K, Palosuo K, Voutilainen H, Pelkonen A, Kauppi P. The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults. Immun Inflamm Dis. 2018;6(2):307–11. https://doi.org/10.1002/iid3.218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nagakura K-I, Sato S, Yanagida N, Nishino M, Asaumi T, Ogura K, Ebisawa M. Oral immunotherapy in Japanese children with anaphylactic peanut allergy. Int Arch Allergy Immunol. 2018;175(3):181–8. https://doi.org/10.1159/000486310.

    Article  CAS  PubMed  Google Scholar 

  18. Wang Y, Kong Y, Wu MX. Innovative systems to deliver allergen powder for epicutaneous immunotherapy. Front Immunol. 2021;12:647954. https://doi.org/10.3389/fimmu.2021.647954.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Liu G, Liu M, Wang J, Mou Y, Che H. The role of regulatory T cells in epicutaneous immunotherapy for food allergy. Front Immunol. 2021;12:660974. https://doi.org/10.3389/fimmu.2021.660974.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chow TG, Parrish C, Bird JA. Food allergy: epicutaneous immunotherapy. J Food Allergy. 2020;2(1):81–5. https://doi.org/10.2500/jfa.2020.2.200016.

    Article  CAS  Google Scholar 

  21. Slovick A, Douiri A, Muir R, Guerra A, Tsioulos K, Hay E, et al. Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol. 2017;139:1830–9.e13. https://doi.org/10.1016/j.jaci.2016.09.024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Senti G, Freiburghaus A, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L, et al. Intralymphatic immunotherapy: update and unmet needs. Int Arch Allergy Immunol. 2019;178:141–9. https://doi.org/10.1159/000493647.

    Article  CAS  PubMed  Google Scholar 

  23. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization Position Paper. Allergy. 2009;64(Suppl 91):1–59. https://doi.org/10.1111/j.1398-9995.2009.02309.x.

    Article  PubMed  Google Scholar 

  24. Passalacqua G, Bagnasco D, Canonica GW. 30 years of sublingual immunotherapy. Allergy. 2020;75:1107–20. https://doi.org/10.1111/all.14113.

    Article  PubMed  Google Scholar 

  25. Machado OLT, Campos-Mesquita DM, Pacheco-Soares T. Antihistaminic treatment, allergen-specific immunotherapy, and blockade of IgE as alternative allergy treatments. In: Athari SS, editor. Allergen, Chapter 4. London: IntechOpen; 2017. p. 67–75. https://doi.org/10.5772/intechopen.69912.

  26. Jensen-Jarolim E, Roth-Walter F, Jordakieva G, Pali-Schöll I. Allergens and adjuvants in allergen immunotherapy for immune activation, tolerance, and resilience. J Allergy Clin Immunol. 2021;9(5):1780–9. https://doi.org/10.1016/j.jaip.2020.12.008.

    Article  CAS  Google Scholar 

  27. Baranyi U, Farkas AM, Hock K, Mahr B, Linhart B, Gattringer M, et al. Cell therapy for prophylactic tolerance in immunoglobulin E-mediated allergy. EBioMedicine. 2016;7:230–9. https://doi.org/10.1016/j.ebiom.2016.03.028.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Esmaeilzadeh E, Tahmasebi S, Athari SS. Chimeric antigen receptor - T cell therapy: applications and challenges in treatment of allergy and asthma. Biomed Pharmacother. 2020;123:109685. https://doi.org/10.1016/j.biopha.2019.109685.

    Article  CAS  PubMed  Google Scholar 

  29. Johnson L, Duschl A, Himly M. Nanotechnology-based vaccines for allergen-specific immunotherapy: potentials and challenges of conventional and novel adjuvants under research. Vaccine. 2020;8:237. https://doi.org/10.3390/vaccines8020237.

    Article  CAS  Google Scholar 

  30. Klimek L, Schmidt-Weber CB, Kramer MF, Skinner MA, Heath MD. Clinical use of adjuvants in allergen-immunotherapy. Expert Rev Clin Immunol. 2017;13(6):599–610. https://doi.org/10.1080/1744666X.2017.1292133.

    Article  CAS  PubMed  Google Scholar 

  31. Kirtland ME, Tsitoura DC, Durham SR, Shamji MH. Toll-like receptor agonists as adjuvants for allergen immunotherapy. Front Immunol. 2020;11:599083. https://doi.org/10.3389/fimmu.2020.599083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Oliver CE. The use of allergoids and adjuvants in allergen immunotherapy. Arch Asthma Allergy Immunol. 2017;1:040–60. https://doi.org/10.29328/journal.haard.1001006.

    Article  Google Scholar 

  33. Klimek L, Fox GC, Thum-Oltmer S. SCIT with a high-dose house dust mite allergoid is well tolerated: safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups. Allergo J Int. 2018;27(5):131–9. https://doi.org/10.1007/s40629-018-0059-x.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Valenta R, Campana R, Focke-Tejkl M, Niederberger V. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol. 2016;137(2):351–7. https://doi.org/10.1016/j.jaci.2015.12.1299.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Nandy A, Creticos PS, Häfner D. Recombinant allergens in specific immunotherapy. In: Kleine-Tebbe J, Jakob T, editors. Molecular allergy diagnostics. Cham: Springer; 2017. https://doi.org/10.1007/978-3-319-42499-6_26.

    Chapter  Google Scholar 

  36. Tsheppe A, Palmberger D, van Rijt L, Kalic T, Mayr V, Palladino C, et al. Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity. J Allergy Clin Immunol. 2019;145(1):229–38. https://doi.org/10.1016/j.jaci.2019.08.036.

    Article  CAS  Google Scholar 

  37. Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018;9:1421. https://doi.org/10.1038/s41467-018-03636-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Klimov VV. Vaccination. In: From basic to clinical immunology. Cham: Springer; 2019. https://doi.org/10.1007/978-3-030-0332301_8.

    Chapter  Google Scholar 

  39. Klimek L, Kündig T, Kramer M, Guethoff S, Jensen-Jarolim E, Schmidt-Weber C, et al. Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. Allergo J Int. 2018;27(8):245–55. https://doi.org/10.1007/s40629-018-0074-y.

    Article  PubMed  PubMed Central  Google Scholar 

  40. López RR, Ocampo I, Sánchez L-M, Alazzam A, Bergeron K-F, Camacho-León S, et al. Surface response based modeling of liposome characteristics in a periodic disturbance mixer. Micromachines (Basel). 2020;11(3):235. https://doi.org/10.3390/mi11030235.

    Article  Google Scholar 

  41. Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF. Is the allergen really needed in allergy immunotherapy? Curr Treat Options Allergy. 2015;2:72–82. https://doi.org/10.1007/s40521-014-0038-5.

    Article  PubMed  Google Scholar 

  42. Caraballo L, Valenta R, Acevedo N, Zakzuk J. Are the terms major and minor allergens useful for precision allergology? Front Immunol. 2021;12:651500. https://doi.org/10.3389/fimmu.2021.651500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Matricardi PM, Dramburg S, Potapova E, Skevaki C, Renz H. Molecular diagnosis for allergen immunotherapy. J Allergy Clin Immunol. 2018;143(3):P831–43. https://doi.org/10.1016/j.jaci.2018.12.1021.

    Article  CAS  Google Scholar 

  44. Feuille E, Nowak-Wegrzyn A. Allergen-specific immunotherapies for food allergy. Allergy Asthma Immunol Res. 2018;10(3):189–206. https://doi.org/10.4168/aair.2018.10.3.189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Schoos A-MM, Bullens D, Chawes BL, De Vlieger L, DunnGalvin A, Epstein MM, et al. Immunological outcomes of allergen-specific immunotherapy in food allergy. Front Immunol. 2020;11:568598. https://doi.org/10.3389/fimmu.2020.568598.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Fuhrmann V, Huang H-J, Akarsu A, Shilovskiy I, Elisyutina O, Khaitov M, et al. From allergen molecules to molecular immunotherapy of nut allergy: a hard nut to crack. Front Immunol. 2021;12:742732. https://doi.org/10.3389/fimmu.2021.742732.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Sood AK, Scurlock AM. Food allergy oral immunotherapy. J Food Allergy. 2020;2(1):75–80. https://doi.org/10.2500/jfa.2020.2.200005.

    Article  CAS  Google Scholar 

  48. Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, et al. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;73(4):799–814. https://doi.org/10.1111/all.13319.

    Article  CAS  PubMed  Google Scholar 

  49. Jones SM, Sicherer SH, Burks AW, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242–52.e9. https://doi.org/10.1016/j.jaci.2016.08.017.

    Article  CAS  PubMed  Google Scholar 

  50. Lee SP, Choi SJ, Joe E, Lee SM, Lee MW, Shim JW, et al. A pilot study of intralymphatic immunotherapy for house dust mite, cat, and dog allergies. Allergy Asthma Immunol Res. 2017;9:272–7. https://doi.org/10.4168/aair.2017.9.3.272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Tonti E, Larché M. Concepts and perspectives on peptide-based immunotherapy in allergy. Allergo J Int. 2016;25:144–53. https://doi.org/10.1007/s40629-016-0121-5.

    Article  Google Scholar 

  52. Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis AA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. https://doi.org/10.1002/alr.22073.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Bao Y, Chen J, Cheng L, Guo Y, Hong S, Kong W, et al. Chinese guideline on allergen immunotherapy for allergic rhinitis. J Thorac Dis. 2017;9(11):4607–50. https://doi.org/10.21037/jtd.2017.10.112.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Robertson K, Montazeri N, Shelke U, Jeimy S, Kim H. A single centre retrospective study of systemic reactions to subcutaneous immunotherapy. Allergy Asthma Clin Immunol. 2020;16:93. https://doi.org/10.1186/s13223-020-00491-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125(3):569–74.e1–7. https://doi.org/10.1016/j.jaci.2009.10.060.

    Article  PubMed  Google Scholar 

  56. Cox L, Nelson H, Lockey R, Contributors W. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(suppl 1):S1–55. https://doi.org/10.1016/j.jaci.2010.09.034.

    Article  PubMed  Google Scholar 

  57. Epstein TG, Calabria C, Cox LS, Dreborg S. Current evidence on safety and practical considerations for administration of sublingual allergen immunotherapy (SLIT) in the United States. J Allergy Clin Immunol Pract. 2017;5(1):34–40.e2. https://doi.org/10.1016/j.jaip.2016.09.017.

    Article  PubMed  Google Scholar 

  58. Lim CE, Sison CP, Ponda P. Comparison of pediatric and adult systemic reactions to subcutaneous immunotherapy. J Allergy Clin Immunol Pract. 2017;5(5):1241–7.e2. https://doi.org/10.1016/j.jaip.2017.01.014.

    Article  PubMed  Google Scholar 

  59. Huang Y, Wang C, Wang X, Zhang L, Lou H. Efficacy and safety of subcutaneous immunotherapy with house dust mite for allergic rhinitis: a meta-analysis of randomized controlled trials. Allergy. 2019;74(1):189–92. https://doi.org/10.1111/all.13583.

    Article  PubMed  Google Scholar 

  60. Arroabarren E, Echechipía S, Galbete A, Lizaso MT, Olaguibel JM, Tabar AI. Association between component-resolved diagnosis of house dust mite allergy and efficacy and safety of specific immunotherapy. J Investig Allergol Clin Immunol. 2019;29(2):164–7. https://doi.org/10.18176/jiaci.0359.

    Article  CAS  PubMed  Google Scholar 

  61. Molina-Sáenz MM, Villa-Arango AM, Cardona-Villa R. Safety of subcutaneous immunotherapy with tyrosine-adsorbed house dust mite extracts in patients with allergic disease. Rev Alerg Mex. 2017;64:52–65.

    PubMed  Google Scholar 

  62. Blome C, Hadler M, Karagiannis E, Kirsch J, Neht C, Kressel N, Augustin M. Relevant patient benefit of sublingual immunotherapy with birch pollen allergen extract in allergic rhinitis: an open, prospective, non-interventional study. Adv Ther. 2020;37:2932–45. https://doi.org/10.6084/m9.figshare.12091017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Novak NM, Buhl T, Pfaa O. Adherence during early allergen immunotherapy and strategies to motivate and support patients. Eur Med J. 2018;3(3):21–9.

    Google Scholar 

  64. Aytekin ES, Soyer Ö, Şekerel BE, Şahiner ÜM. Subcutaneous allergen immunotherapy in children: real life compliance and effect of COVID-19 pandemic on compliance. Int Arch Allergy Immunol. 2021;182:631–6. https://doi.org/10.1159/000514587.

    Article  CAS  PubMed  Google Scholar 

  65. Bovermann X, Ricklefs I, Vogelberg C, Klimek L, Kopp MV. Accelerated dose escalation with 3 injections of an aluminum hydroxide-adsorbed allergoid preparation of 6 grasses is safe for children and adolescents with moderate to severe allergic rhinitis. Int Arch Allergy Immunol. 2021;182:524–34. https://doi.org/10.1159/000512561.

    Article  CAS  PubMed  Google Scholar 

  66. Martínez FJS, Piñana VL, González-Mancebo E, Villajos IS-G, García-González F, Sánchez-Hernández C, et al. Observational study on the tolerability of cluster subcutaneous immunotherapy in patients with rhinoconjunctivitis with or without asthma sensitized to pollen: The SIMO study. Saf Health. 2018;4:6. https://doi.org/10.1186/s40886-018-0074-0.

    Article  Google Scholar 

  67. Fokkens W, van Maaren M, Wolvers M, van Wijk RG. Rush immunotherapy with multiple aeroallergens is safe in an adult population. Rhinol Online. 2018;1:35–7. https://doi.org/10.4193/RHINOL/18.019.

    Article  Google Scholar 

  68. Alustal House Dust Mites Extract initial treatment set. 2019. https://www.healthdirect.gov.au/medicines/brand/amt,63041000168103/alustal-house-dust-mites-extract-initial-treatment-set.

  69. Staloral. Evidence is difference. Sublingual solution of allergen extracts for immunotherapy. Monograph. Stallergenes; 2011. p. 1–68.

    Google Scholar 

  70. Acosta GS, Kinaciyan T, Kitzmüller C, Möbs C, Pfützner W, Bohle B. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy. J Allergy Clin Immunol. 2020;146(4):894–900.e2. https://doi.org/10.1016/j.jaci.2020.03.015.

    Article  CAS  Google Scholar 

  71. Huber S, Lang R, Steiner M, Aglas L, Ferreira F, Wallner M, et al. Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT. Clin Transl Allergy. 2018;8:39. https://doi.org/10.1186/s13601-018-0226-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Hoh RA, Joshi SA, Liu Y, Wang C, Roskin KM, Lee J-Y, et al. Single B-cell deconvolution of peanut-specific antibody responses in allergic patients. J Allergy Clin Immunol. 2016;137(1):157–67. https://doi.org/10.1016/j.jaci.2015.05.029.

    Article  CAS  PubMed  Google Scholar 

  73. Gotoh M, Kaminuma O. Sublingual immunotherapy: how sublingual allergen administration heals allergic diseases; current perspective about the mode of action. Pathogens. 2021;10:147. https://doi.org/10.3390/pathogens10020147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Gratz IK, Campbell DJ. Organ-specific and memory Treg cells: specificity, development, function, and maintenance. Front Immunol. 2014;5:333. https://doi.org/10.3389/fimmu.2014.00333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Yao Y, Wang N, Chen C-L, Pan L, Wang Z-C, Yunis J, et al. CD23 expression on switched memory B cells bridges T-B cell interaction in allergic rhinitis. Allergy. 2020;75(10):2599–612. https://doi.org/10.1111/all.14288.

    Article  CAS  PubMed  Google Scholar 

  76. Rhyou H-I, Nam Y-H. Efficacy of allergen immunotherapy for allergic asthma in real world practice. Allergy Asthma Immunol Res. 2020;12(1):99–109. https://doi.org/10.4168/aair.2020.12.1.99.

    Article  CAS  PubMed  Google Scholar 

  77. Justicia JL, Padrò C, Roger A, Moreno F, Rial MJ, Parra A, et al. Immunological parameters as biomarkers of response to microcrystalline tyrosine-adjuvanted mite immunotherapy. World Allergy Organ J. 2021;14(6):1000545. https://doi.org/10.1016/j.waojou.2021.100545.

    Article  CAS  Google Scholar 

  78. Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen Q-A, Speake C, et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Sci Transl Med. 2017;9(401):eaam9171. https://doi.org/10.1126/scitranslmed.aam9171.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Wambre E. Effect of allergen-specific immunotherapy on CD4+ T cells. Curr Opin Allergy Clin Immunol. 2015;15(6):581–7. https://doi.org/10.1097/ACI.0000000000000216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Komlósi ZI, Kovács N, Sokolowska M, van de Veen W, Akdis M, Akdis CA. Mechanisms of subcutaneous and sublingual aeroallergen immunotherapy. What is new? Immunol Allergy Clinics. 2020;40(1):P1–14. https://doi.org/10.1016/j.iac.2019.09.009.

    Article  Google Scholar 

  81. Schulten V, Tripple V, Seumois G, et al. Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells. J Allergy Clin Immunol. 2018;141(2):775–7.e6. https://doi.org/10.1016/j.jaci.2017.04.032.

    Article  CAS  PubMed  Google Scholar 

  82. Yao Y, Wang Z-C, Wang N, Zhou P-C, Chen C-L, Song J, et al. Allergen immunotherapy improves defective follicular regulatory T cells in patients with allergic rhinitis. J Allergy Clin Immunol. 2019;144(1):118–28. https://doi.org/10.1016/j.jaci.2019.02.008.

    Article  CAS  PubMed  Google Scholar 

  83. Matsuoka T, Shaji MH, Durham SR. Allergen immunotherapy and tolerance. Allergol Int. 2013;62:403–13. https://doi.org/10.2332allergolint.13-RAI-0650.

    Article  CAS  Google Scholar 

  84. Steveling-Klein EH. Allergen-specific immunotherapy. Eur Med J. 2016;1(4):78–87.

    Google Scholar 

  85. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133:621–31. https://doi.org/10.1016/j.jaci.2013.12.1088.

    Article  CAS  PubMed  Google Scholar 

  86. Kucuksezer UC, Ozdemir C, Cevhertas L, Ogulur I, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergol Int. 2020;69(4):549–60. https://doi.org/10.1016/j.alit.2020.08.002.

    Article  CAS  PubMed  Google Scholar 

  87. Drazdauskaitè G, Layhadi JA, Shamji MH. Mechanisms of allergen immunotherapy in allergic rhinitis. Curr Allergy Asthma Rep. 2021;21:2. https://doi.org/10.1007/s11882-020-00977-7.

    Article  Google Scholar 

  88. Wisniewski J, Agrawal R, Woodfolk JA. Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts. Clin Exp Allergy. 2013;43(2):164–76. https://doi.org/10.1111/cea.12016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Calzada D, Baos S, Cremades-Jimeno L, Cardaba B. Immunological mechanisms in allergic diseases and allergen tolerance: the role of Treg cells. J Immunol Res. 2018;2018:6012053. https://doi.org/10.1155/2018/6012053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. van de Veen W, Akdis M. Tolerance mechanisms of allergen immunotherapy. Allergy. 2019;75(5):1017–8. https://doi.org/10.1111/all.14126.

    Article  Google Scholar 

  91. Zissler UM, Schmidt-Weber CB. Predicting success of allergen-specific immunotherapy. Front Immunol. 2020;11:1826. https://doi.org/10.3389/fimmu.2020.01826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Xian M, Feng M, Dong Y, Su Q, Li J. Changes in CD4+CD25+FoxP3+ regulatory T cells and serum cytokines in sublingual and subcutaneous immunotherapy in allergic rhinitis with or without asthma. Int Arch Allergy Immunol. 2020;181(1):71–80. https://doi.org/10.1159/000503143.

    Article  CAS  PubMed  Google Scholar 

  93. Boonpiyathad T, Sokolowska M, Morita H, Ruckert B, Kast JI, Wawrzyniak M, et al. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy. Allergy. 2019;74(5):976–85. https://doi.org/10.1111/all.13684.

    Article  CAS  PubMed  Google Scholar 

  94. Eljaszewicz A, Ruchti F, Radzikowska U, Globinska A, Boonpiyathad T, Gschwend A, et al. Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy. J Allergy Clin Immunol. 2021;147:1865–77.

    Article  CAS  Google Scholar 

  95. Guilliams M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. Immunity. 2018;49:595–613. https://doi.org/10.1016/j.immuni.2018.10.005.

    Article  CAS  PubMed  Google Scholar 

  96. Kerage D, Sloan EK, Mattarollo SR, McCombe PA. Interaction of neurotransmitters and neurochemicals with lymphocytes. J Neuroimmunol. 2019;332:99–111. https://doi.org/10.1016/j.jneuroim.2019.04.006.

    Article  CAS  PubMed  Google Scholar 

  97. Zouali M. Immunological tolerance: mechanisms. In: eLS. Paris: Wiley; 2007. p. 1–9. https://doi.org/10.1002/9780470015902.a0000950.pub2.

    Chapter  Google Scholar 

  98. Leung NYH, Wai CYY, Shu SA, Chang CC, Chu KH, Leung PSC. Low-dose allergen-specific immunotherapy induces tolerance in a murine model of shrimp allergy. Int Arch Allergy Immunol. 2017;174:86–96. https://doi.org/10.1159/000479694.

    Article  CAS  PubMed  Google Scholar 

  99. Ciprandi G, Silvestri M. Serum specific IgE: a biomarker of response to allergen immunotherapy. J Investig Allergol Clin Immunol. 2014;24(1):35–9.

    CAS  PubMed  Google Scholar 

  100. Kouser L, Kappen J, Walton RP, Shamji MH. Update on biomarkers to monitor clinical efficacy response during and post treatment in allergen immunotherapy. Curr Treat Options Allergy. 2017;4:43–53. https://doi.org/10.1007/s40521-017-0117-5.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Ma T-T, Cao M-D, Yu R-L, Shi H-Y, Yan W-J, Liu J-G, et al. Leukotriene A4 hydrolase is a candidate predictive biomarker for successful allergen immunotherapy. Front Immunol. 2020;11:559748. https://doi.org/10.3389/fimmu.2020.559746.

    Article  CAS  Google Scholar 

  102. Czolk R, Klueber J, Sørensen M, Wilmes P, Codreanu-Morel F, Skov PS, et al. IgE-mediated peanut allergy: current and novel predictive biomarkers for clinical phenotypes using multi-omics approaches. Front Immunol. 2021;11:594350. https://doi.org/10.3389/fimmu.2020.594350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Sindher SB, Long A, Acharya S, Sampath V, Nadeau KC. The use of biomarkers to predict aero-allergen and food immunotherapy responses. Clin Rev Allergy Immunol. 2018;55:190–204. https://doi.org/10.1007/s12016-018-8678-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Hardy LC, Smeekens JM, Kullis MD. Biomarkers in food allergy immunotherapy. Curr Allergy Asthma Rep. 2019;19(12):61. https://doi.org/10.1007/s11882-019-0894-y.

    Article  CAS  PubMed  Google Scholar 

  105. Shamji MH, Kappen JH, Akdis M, Jensen-Jarolim E, Knol E, Kleine-Tebbe J, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI position paper. Allergy. 2017;72(8):1156–73. https://doi.org/10.1111/all.13138.

    Article  CAS  PubMed  Google Scholar 

  106. Wang W, Yin J, Wang X, Ma T, Lan T, Song Q, Guo Y. Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study. Allergy Asthma Clin Immunol. 2020;16:18. https://doi.org/10.1186/s13223-020-0416-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. van Bilsen JHM, Verschuren L, Wagenaar L, Vonk MM. A network-based approach for identifying suitable biomarkers for oral immunotherapy of food allergy. BMC Bioinformatics. 2019;20(1):206. https://doi.org/10.1186/s12859-019-2802-9.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Hoof I, Schulten V, Layhadi JA, Stranzl T, Christensen LH, de la Mata SH, et al. Allergen-specific IgG+ memory B cells are temporally linked to IgE memory responses. J Allergy Clin Immunol. 2020;146(1):180–91. https://doi.org/10.1016/j.jaci.2019.11.046.

    Article  CAS  PubMed  Google Scholar 

  109. van Zelm MC, McKenzie CI, Varese N, Rolland JM, O'Hehir RE. Recent developments and highlights in immune monitoring of allergen immunotherapy. Allergy. 2019;74:2342–54. https://doi.org/10.1111/all.14078.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Immunology and Allergy Department, Siberian State Medical University, Tomsk, Russia

    Vladimir V. Klimov

Authors
  1. Vladimir V. Klimov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vladimir V. Klimov .

8.1 Electronic Supplementary Material

Audio 8.1

(MP3 15850 kb)

Audio 8.2

(MP3 10519 kb)

Audio 8.3

(MP3 9138 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Klimov, V.V. (2022). Allergen-Specific Immunotherapy (AIT). In: Textbook of Allergen Tolerance . Springer, Cham. https://doi.org/10.1007/978-3-031-04309-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-04309-3_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-04308-6

  • Online ISBN: 978-3-031-04309-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation